Tandem Diabetes Care Inc
NASDAQ:TNDM
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Dell Technologies Inc
NYSE:DELL
|
Technology
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Abercrombie & Fitch Co
NYSE:ANF
|
Retail
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
S&P Global Inc
NYSE:SPGI
|
Financial Services
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
Citigroup Inc
NYSE:C
|
Banking
|
| IE |
|
Iterum Therapeutics PLC
NASDAQ:ITRM
|
Pharmaceuticals
|
| US |
|
Medpace Holdings Inc
NASDAQ:MEDP
|
Life Sciences Tools & Services
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
19.05
53.43
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
Dell Technologies Inc
NYSE:DELL
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Abercrombie & Fitch Co
NYSE:ANF
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
S&P Global Inc
NYSE:SPGI
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
Citigroup Inc
NYSE:C
|
US |
|
|
Iterum Therapeutics PLC
NASDAQ:ITRM
|
IE |
|
|
Medpace Holdings Inc
NASDAQ:MEDP
|
US |
This alert will be permanently deleted.
Tandem Diabetes Care Inc
Tandem Diabetes Care Inc
Net Issuance of Debt
Tandem Diabetes Care Inc
Net Issuance of Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Tandem Diabetes Care Inc
NASDAQ:TNDM
|
Net Issuance of Debt
$60.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Becton Dickinson and Co
NYSE:BDX
|
Net Issuance of Debt
$3.8B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Net Issuance of Debt
$1.6B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
|
Stryker Corp
NYSE:SYK
|
Net Issuance of Debt
$2.4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
17%
|
CAGR 10-Years
7%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Net Issuance of Debt
-$2.4B
|
CAGR 3-Years
-257%
|
CAGR 5-Years
12%
|
CAGR 10-Years
-18%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Net Issuance of Debt
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Tandem Diabetes Care Inc
Glance View
Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. The company is headquartered in San Diego, California and currently employs 2,000 full-time employees. The company went IPO on 2013-11-13. The firm is focused on the design, development, and commercialization of technology solutions for people living with diabetes. The firm's manufacturing, sales, and support activities principally focus on its flagship pump platform, the t:slim X2, and its complementary product offerings. Its t:slim X2 is based on Company's technology platform and is the smallest durable insulin pump available in the United States. The firm has commercially offered two different automated insulin dosing (AID) algorithms on t:slim X2, including Control-IQ technology, which is an advanced hybrid-closed loop feature, designed to help increase a user's time in their targeted glycemic range, and Food and Drug Administration (FDA) to deliver automatic correction boluses in addition to adjusting insulin to help prevent high and low blood sugar based on continuous glucose monitoring (CGM) readings.
See Also
What is Tandem Diabetes Care Inc's Net Issuance of Debt?
Net Issuance of Debt
60.7m
USD
Based on the financial report for Sep 30, 2024, Tandem Diabetes Care Inc's Net Issuance of Debt amounts to 60.7m USD.
You don't have any saved screeners yet
